文献速递银屑病与炎症性皮肤病

银屑病病史患者全身糖皮质激素暴露后的银屑病发作

Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis.
PubMed 文献 · JAMA Dermatol · 2021-01-01

结果显示,首次疗程期间任何类型银屑病发作率为1.42%(95%CI,0.72%-2.44%),仅1例严重发作(红皮病),无脓疱型发作(0.07%;95%CI,0.00%-0.26%)。作者认为全身激素诱发严重发作的可能性可能远低于传统教学所述。

要点

  • 首次全身糖皮质激素疗程期间或停药3个月内任何类型银屑病发作率为1.42%(95%CI,0.72%-2.44%)。
  • 全部发作中仅1例严重发作(红皮病),无脓疱型银屑病发作(0.07%;95%CI,0.00%-0.26%)。
  • 结果提示全身激素诱发严重银屑病发作的可能性可能低于传统认识。

核心结论

  • 在有银屑病病史的成人中,首次全身糖皮质激素疗程期间或停药3个月内的银屑病发作率较低,尤其是严重发作。
  • 作者认为全身激素触发严重发作的可能性可能远低于皮肤病学传统教学所述。

研究设计与样本

  • 排除18岁以下、诊断为银屑病关节炎、以及仅接受外用、关节腔内或滑囊内糖皮质激素的患者。
  • 共516例队列患者,其中288例(55.8%)为女性,首次银屑病诊断时平均(SD)年龄为49.6(17.0)岁。

主要发现

  • 在1970例接受全身糖皮质激素前已诊断银屑病的患者中,首次疗程期间任何类型银屑病发作率为1.42%(95%CI,0.72%-2.44%)。
  • 进一步分层显示全部报告的发作中仅1例严重发作(红皮病),无脓疱型银屑病发作(0.07%;95%CI,0.00%-0.26%)。

关键数值与推荐

  • 主要结局为首次全身糖皮质激素疗程期间或停药3个月内的银屑病发作率。
  • 次要指标包括特定类型银屑病发作率,包括脓疱型、红皮病型和斑块期加重。
  • 任何类型发作率1.42%(95%CI,0.72%-2.44%);严重发作(红皮病)0.07%(95%CI,0.00%-0.26%),无脓疱型发作。

临床怎么用

  • 对有银屑病病史患者处方全身糖皮质激素时,可参考本研究中较低的发作率,尤其是严重发作率。
  • 仍需结合患者个体情况评估风险,不应据本研究完全否定对严重发作的警惕。

局限性

  • 本研究为回顾性队列研究,仅来自单一健康系统。
  • 仅评估首次全身糖皮质激素疗程,未涉及多次或长期暴露。
  • 排除银屑病关节炎患者,结论不适用于该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To our knowledge, this study is the first to assess the rate of any type of psoriasis flare during or immediately following the administration of systemic corticosteroids in patients with a known history of psoriasis. OBJECTIVE: To determine the rates and types of psoriasis flares during or within 3 months after concluding systemic corticosteroid administration in adult patients with a known history of psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study assessed adult patients (≥18 years at the time of psoriasis diagnosis) evaluated in the Marshfield Clinic Health System (Marshfield, Wisconsin) with an established diagnosis of psoriasis and exposure to at least 1 systemic corticosteroid from October 31, 2012, to July 1, 2018. Exclusion criteria were patients younger than 18 years, patients with a diagnosis of psoriatic arthritis, and patients receiving only topical, intraarticular, or intrabursal corticosteroids. MAIN OUTCOMES AND MEASURES: The primary outcome was rate of psoriasis flares during or within 3 months of discontinuation of the patient's first course of systemic corticosteroids. Secondary measures included rates of specific types of psoriasis flares, including pustular, erythrodermic, and worsening plaque stage psoriasis. RESULTS: Of 516 cohort patients, 288 (55.8%) were women, and the mean (SD) age at first psoriasis diagnosis was 49.6 (17.0) years. Among 1970 patients with a diagnosis of psoriasis before receiving systemic corticosteroids, a 1.42% (95% CI, 0.72%-2.44%) psoriasis flare rate of any type was identified when prescribed their first course of systemic corticosteroids. Further stratification identified only 1 severe flare (erythroderma) among all flares reported, with no pustular psoriasis flares identified (0.07%; 95% CI, 0.00%-0.26%). CONCLUSIONS AND RELEVANCE: In this study, the rates of psoriasis flares were low, especially for severe psoriasis flares. Our results suggest that systemic steroids may be much less likely to trigger severe flares in patients with psoriasis than what is traditionally taught in dermatology.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Gregoire ARF, DeRuyter BK, Stratman EJ, et al. Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis. JAMA Dermatol. 2021. PMID: 33206132. doi:10.1001/jamadermatol.2020.4219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。